Dialogue with third-party payers
would be encouraged.
The defendant drug companies' conspiracy to prevent the sale of the generic version of Cardizem CD denied consumers and third-party payers
the opportunity to use a significantly less costly generic equivalent.
The practice of medicine is business, and third-party payers
are part of the medical-industrial complex.
In both the national settlement and the Massachusetts settlement, consumers will receive 11 percent of the settlement fund with the balance going to third-party payers
didn't contribute to implementation of guidelines through support systems and staff.
In every aspect of health care, trends point toward increasing use of data collection to satisfy the demands of third-party payers
, the government and others wanting proof that a facility is meeting standards of quality.
Among the key variables are the program type (for example, transitional medical, general rehabilitation), specialized or general services, anticipated payer mix (both initially and over time), availability of professional staff in the labor market, unit size, and the expectations of third-party payers
and patients have expressed concern over the high cost of anticancer biologics, denying off-label use or forgoing treatment altogether.
To that end, the following are the criteria that managed care, other third-party payers
and potential referral sources will use to judge your infusion therapy program:
Independent physicians are responding to these changes by creating their own delivery systems that market their services to patients, health plans, and other third-party payers
Among the factors that could cause actual results to differ materially are the following: the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers
in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; and the risk factors reported from time to time in the Company's SEC reports.
Although large third-party payers
, notably NIedicare, Medicaid, and some of the larger Blue Cross/Blue Shield plans, did enjoy enough market power to exercise varying degrees of control over the prices of health services, the principle of free choice robbed all third-party payers
of the leverage to manage the volume of services going into treating patients.